Ensysce Biosciences Announces Initiation Of Second Human Abuse Potential Study, Being Conducted By Dr. Vince Clinical Research
~ Oral Opioid Abuse Being Explored for PF614 ~
~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~
SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce
Alvotech And STADA Increase Access To Adalimumab For Patients In Switzerland With The Launch Of Hukyndra
Hukyndra® increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab
Exclusive partnership between Alvotech and STADA in Europe includes
Vir Biotechnology Announces First Patient Dosed In The Phase 2 SOLSTICE Trial Evaluating VIR-2218 And VIR-3434 For The Treatment Of Chronic Hepatitis D Virus Infection
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the first patient has been dosed in the Phase 2 SOLSTICE clinical trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of
Medicenna Presents Preclinical Data At Cytokines 2022
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer
--IL-4/IL-13
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy.
Tonix Pharmaceuticals Highlights Presentation At IASP 2022 World Congress On Pain
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS
Approximately 50% of Long COVID Patients with
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands
Novartis AG (NYSE:NVS) has revealed insights into the updated company strategy. The company said that a ‘US-first’ mindset, increasing the…
AstraZeneca Announced Lynparza Approved in China for Ovarian Cancer
AstraZeneca and MSD's Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab, and whose cancer is associated with homologous recombination deficiency (HRD)-positive statu
FDA Approves Lilly’s Retevmo for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
Eli Lilly and Company (NYSE: LLY) today announced the U.S.